We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
-1.9%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$647M
AUM Growth
-$194M
(-23%)
Cap. Flow
+$33.7M
Cap. Flow
% of AUM
5.2%
Top 10 Holdings %
Top 10 Hldgs %
63.34%
Holding
208
New
51
Increased
38
Reduced
42
Closed
71
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVO
Novo Nordisk
NVO
|
+$20.4M |
| 2 |
Nektar Therapeutics
NKTR
|
+$14.1M |
| 3 |
Xeris Biopharma Holdings
XERS
|
+$8.7M |
| 4 |
ESPR
Esperion Therapeutics
ESPR
|
+$6.56M |
| 5 |
NTBL
Notable Labs, Ltd. Ordinary Shares
NTBL
|
+$4.27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$12M |
| 2 |
Biogen
BIIB
|
+$8.66M |
| 3 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
+$3.63M |
| 4 |
Cogent Biosciences
COGT
|
+$3.16M |
| 5 |
Incyte
INCY
|
+$2.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 73.46% |
| 2 | Healthcare | 26.22% |
| 3 | Consumer Staples | 0.17% |
| 4 | Financials | 0.05% |
| 5 | Industrials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
PUT
Insmed
INSM
$26.2B
| $3.93M | 0.61% |
1,661
+1,118
| +206% | +$28.8K |
|
|
GBT
27
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.78M | 0.58% |
836
+78
| +10% | +$3.55K |
|
|
BCLI
28
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $3.63M | 0.56% |
61,982
+60,494
| +4,065% | +$3.56M |
|
|
ISEE
29
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $3.58M | 0.55% |
+1,310,078
| New | +$3.61M |
|
|
SSKN
30
DELISTED
Strata Skin Sciences
SSKN
| $3.45M | 0.53% |
168,228
+136,653
| +433% | +$2.23M |
|
|
AMRN
31
CALL
Amarin Corp
AMRN
$294M
| $3.31M | 0.51% |
535
+119
| +29% | +$7.37K |
|
|
32
CALL
Nektar Therapeutics
NKTR
$2.28B
| $3.19M | 0.49% |
44
-4
| -8% | -$4.61K |
|
33
Genprex
GNPX
$2.71M
| $3.17M | 0.49% |
+9
| New | +$3.53M |
|
34
Outlook Therapeutics
OTLK
$164M
| $3.12M | 0.48% |
23,080
+9,903
| +75% | +$1.46M |
|
|
35
Incyte
INCY
$24.7B
| $2.77M | 0.43% |
41,419
-40,442
| -49% | -$2.77M |
|
|
EOCN
36
Eocene Ltd. Ordinary Shares
EOCN
$3.88M
| $2.76M | 0.43% |
+161
| New | +$1.86M |
|
|
AVEO
37
CALL
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $2.76M | 0.43% |
1,221
+364
| +42% | +$8.63K |
|
|
38
PUT
Incyte
INCY
$24.7B
| $2.72M | 0.42% |
406
-889
| -69% | -$60.8K |
|
39
AstraZeneca
AZN
$251B
| $2.4M | 0.37% |
+34,232
| New | +$2.46M |
|
|
SGMO
40
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $2.39M | 0.37% |
168,239
+26,103
| +18% | +$434K |
|
|
KYNB
41
PUT
Kyntra Bio
KYNB
$31.5M
| $2.29M | 0.35% |
+15
| New | +$19.6K |
|
|
FOLD
42
PUT
DELISTED
Amicus Therapeutics
FOLD
| $2.24M | 0.35% |
1,436
+436
| +44% | +$6.59K |
|
43
CALL
Madrigal Pharmaceuticals
MDGL
$12.1B
| $2.24M | 0.35% |
+80
| New | +$14K |
|
|
ZSAN
44
DELISTED
Zosano Pharma Corporation
ZSAN
| $2.04M | 0.32% |
14,306
+7,627
| +114% | +$1.15M |
|
|
ADVM
45
CALL
DELISTED
Adverum Biotechnologies
ADVM
| $1.96M | 0.3% |
371
+277
| +295% | +$16.7K |
|
|
CYTR
46
DELISTED
CytRx Corp
CYTR
| $1.89M | 0.29% |
+1,674,431
| New | +$2.5M |
|
|
SLNO
47
DELISTED
Soleno Therapeutics
SLNO
| $1.84M | 0.28% |
52,397
-8,792
| -14% | -$258K |
|
|
TSRO
48
CALL
DELISTED
TESARO, Inc.
TSRO
| $1.47M | 0.23% |
+331
| New | +$16.1K |
|
49
PUT
MannKind Corp
MNKD
$1.14B
| $1.46M | 0.23% |
4,550
+1,326
| +41% | +$2.48K |
|
|
ESPR
50
CALL
DELISTED
Esperion Therapeutics
ESPR
| $1.45M | 0.22% |
370
-168
| -31% | -$8.49K |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q2 2018 Portfolio in Review
As of Q2 2018, Sabby Management held 208 positions worth $647M, down 23% from $841M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Sabby Management deployed $33.7M of net new capital in Q2 2018, opening 51 new positions and adding to 38 existing holdings. Its largest new stake was Novo Nordisk: 858,710 shares worth $19.8M.
By sector, the portfolio is most concentrated in Miscellaneous at 73% of assets, down from 83% a quarter earlier, followed by Healthcare and Consumer Staples.
On the sell side, the largest reduction was Biogen, an estimated $8.66M trimmed.
- Sabby Management's largest Q2 2018 buy was Novo Nordisk: 858,710 shares worth $19.8M.
- Sabby Management added most to Nektar Therapeutics in Q2 2018, an estimated $14.1M increase.
- Sabby Management's biggest Q2 2018 reduction was Biogen, cutting an estimated $8.66M.
- Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2018, selling an estimated $12M.
- Sabby Management's ten largest holdings make up 63% of its $647M portfolio in Q2 2018.
- Sabby Management opened 51 new positions and closed 71 in Q2 2018.
- Sabby Management's portfolio value fell 23% quarter-over-quarter to $647M.
Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.